VERAXA Biotech (NASDAQ: VRXA) has initiated cell line development for its lead BiTAC(R) T-cell engager (BiTAC-TCE) program, selecting ATUM to support manufacturing development as the candidate advances toward IND/CTA-enabling studies. The collaboration represents an important development milestone, supporting manufacturing, analytical development and nonclinical studies required before clinical testing.
ATUM will apply its Leap-In Transposase(R) technology to generate stable clonal cell lines for VERAXA's lead therapeutic candidate. VERAXA's BiTAC platform is designed to improve the selectivity of T-cell engagers, potentially reducing toxicity associated with conventional approaches. The company recently expanded its research facilities in Heidelberg, Germany, increasing laboratory capacity as multiple oncology programs move toward clinical development.
According to VERAXA, the collaboration with ATUM is intended to streamline the path to IND/CTA-enabling studies. The company's BiTAC-TCE program is its most advanced oncology candidate, and this step is critical for producing the material needed for toxicology and other regulatory studies.
VERAXA Biotech is an emerging leader in designing novel cancer therapies. The company's proprietary BiTAC platform aims to create more selective T-cell engagers that can target tumors while sparing healthy tissues, potentially offering a better safety profile than existing immunotherapies. The initiation of cell line development signals that VERAXA is moving its lead program from research into preclinical development.
For more information on VERAXA Biotech and its programs, visit the company's newsroom at https://ibn.fm/VRXA. For full terms of use and disclaimers, see http://IBN.fm/Disclaimer.
